Faes Farma SA
MAD:FAE
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| ES |
F
|
Faes Farma SA
MAD:FAE
|
1.7B EUR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
993.1B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
587B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
286.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
235.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
239B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
304.3B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
158.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.7B USD |
Loading...
|
Market Distribution
| Min | -178.8% |
| 30th Percentile | 38.9% |
| Median | 52.5% |
| 70th Percentile | 65.1% |
| Max | 192.7% |
Other Profitability Ratios
Faes Farma SA
Glance View
Faes Farma SA, a notable player in the pharmaceutical arena, has orchestrated its operations with the precision of a seasoned conductor. Rooted in Spain with an impressive international reach, the company blends research prowess with adept production capabilities. Central to its modus operandi is the development, manufacture, and commercialization of a wide range of pharmaceutical products and nutritional supplements. With science as its guiding star, Faes Farma dedicates substantial resources to research and development, ensuring a pipeline filled with innovative treatments that cater to diverse medical needs. The company has carved its niche by focusing on therapeutic areas such as allergy, dermatology, and the central nervous system, allowing it to create specialized solutions that resonate well with healthcare providers and patients alike. The company’s revenue engine is driven primarily by its robust product sales, enhanced by strategic partnerships and licensing agreements that bolster its market presence both in Spain and across global markets. Through rigorous production processes, Faes Farma ensures the delivery of high-quality medications, matching industry standards and fostering consumer trust. Additionally, its geographical diversification, with subsidiaries and distribution channels spreading across Europe, Latin America, and Africa, underpins its economic durability. By marrying innovation with strategic commercial tactics, Faes Farma has deftly navigated the complexities of the pharmaceutical landscape, ensuring not only profitability but also the sustained delivery of health-enhancing products to the global community.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Faes Farma SA is 65.1%, which is below its 3-year median of 65.8%.
Over the last 3 years, Faes Farma SA’s Gross Margin has increased from 63.3% to 65.1%. During this period, it reached a low of 63.3% on Sep 30, 2022 and a high of 66.5% on Jun 30, 2024.